Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-04-27
2010-06-29
Peng, Bo (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100
Reexamination Certificate
active
07745593
ABSTRACT:
The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response.
REFERENCES:
patent: 5525714 (1996-06-01), Van Broeckhoven et al.
patent: 5942607 (1999-08-01), Freeman et al.
patent: WO 95/03408 (1995-02-01), None
patent: WO 95/06738 (1995-03-01), None
patent: WO 99/47558 (1999-09-01), None
patent: WO 99/57295 (1999-11-01), None
Stephen Hash, Cloning, Sequencing, Expression and Characterization of the Feline CD28/CD80 Accessory Signaling Complex, May 1997, PhD Dissertation, Texas A&M University, 168 pages.
Sands et al. Molecular Pharmacology, 1994, vol. 45, pp. 932-943.
Akeson, A.L., “A fluorometric assay for the quantitation of cell adherence to endothelial cells,”Journal of Immunological Methods, vol. 163, pp. 181-185 (1993).
Allison, J.P. et al., “Structure, Function, and Serology of the T-cell Antigen Receptor Complex,”Annu. Rev. Immunol., vol. 5, pp. 503-540 (1987).
Allison, J.P., “CD28-B7 interaction in T-cell activation,”Current Opinion in Immunology, vol. 6, pp. 414-419 (1994).
Anderson, P. et al., “Regulatory interactions between members of the immunoglobulin superfamily,”Immunology Today, vol. 9, Nos. 7 and 8, pp. 199-203 (1988).
Antonia, S.J. et al., “B7-1 Expression by a Non-Antigen Presenting Cell-derived Tumor,”Cancer Research, vol. 55, pp. 2253-2256 (1995).
Argyle, D.J. et al., “Nucleotide and predicted peptide sequence of feline interferon-gamma (IFN-y),”DNA Sequence—The Journal of Sequencing and Mapping, vol. 5, pp. 169-171 (1995).
Arima, T. et al., “Inhibition by CTLA4Ig of Experimental Allergic Encephalomyelitis,”The Journal of Immunology, vol. 156, pp. 4916-4924 (1996).
Arruffo, A., et al., “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system,”Proc. Natl. Acad. Sci. USA, vol. 84, pp. 8573-8577 (1987).
Asjo, B. et al., “A Novel Mode of Human Immunodeficiency Virus Type 1 (HIV-1) Activation: Ligation of CD28 Alone Induces HIV-1 Replication in Naturally Infected Lymphocytes,”Journal of Virology, vol. 67, No. 7, pp. 4395-4398 (1993).
Azuma, M. et al., “Functional Expression of B7/BB1 on Activated T Lymphocytes,”J. Exp. Med., vol. 177, pp. 845-850 (1993).
Azuma, M. et al., “Involvement of CD28 in MHC-Unrestricted Cytotoxicity Mediated by a Human Natural Killer Leukemia Cell Line,”The Journal of Immunology, vol. 149, No. 4, pp. 1115-1123 (1992).
Azuma, M. et al., “Requirements for CD28-Dependent T Cell-Mediated Cytotoxicity,”The Journal of Immunology, vol. 150, No. 6, pp. 2091-2101 (1993).
Azuma, M. et al.,“B70 antigen is a second ligand for CTLA-4 and CD28,”Nature, vol. 366, pp. 76-79 (1993).
Bajorath, J. et al., “Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86),”Protein Science, vol. 3, pp. 2148-2150 (1994).
Bajorath, J. et al., “Knowledge-based model building of proteins: Concepts and examples,” Protein Science, vol. 2, pp. 1798-1810 (1993).
Balzano, C. et al., “CTLA-4 and CD28: Similar Proteins, Neighbouring Genes,”Int. J. Cancer: Supplement, vol. 7, pp. 28-32 (1992).
Barcy, S. et al., “FcR cross-linking on monocytes results in impaired T cell stimulatory capacity,”International Immunology, vol. 7, No. 2, pp. 179-189 (1995).
Beale, D., “A Comparison of the Amino Acid Sequences of the Extracellular Domains of the Immunoglobulin Superfamily. Possible Correlations Between Conservancy and Conformation,”Comp. Biochem. Physiol., vol. 80B, No. 2, pp. 181-194 (1985).
Bellone, M. et al., “In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen presenting cells,”Eur. J. Immunol., vol. 24, pp. 2691-2698 (1994).
Berke, G., “The Binding and Lysis of Target Cells by Cytotoxic Lymphocytes: Molecular and Cellular Aspects,”Annu. Rev. Immunol., vol. 12, pp. 735-773 (1994).
Berke, G., “The Functions and Mechanisms of Action of Cytolytic Lymphocytes,”Fundamental Immunology, (W. Paul), New York: Raven Publ. 3d ed., pp. 965-1014 (1993).
Boise, L.H. et al., “CD28 Costimulation Can Promote T Cell Survival by Enhancing the Expression of Bcl-xL,”Immunity, vol. 3, pp. 87-98 (1995).
Brinchmann, J.E. et al., “Expression of Costimulatory Molecule CD28 on T Cells in Human Immunodeficiency Virus Type I Infection: Functional and Clinical Correlations,”The Journal of Infectious Diseases, vol. 169, pp. 730-738 (1994).
Brown, W.C. et al., “Feline Immunodeficiency Virus Infects Both CD4+and CD8+T Lymphocytes,”Journal of Virology, vol. 65, No. 6, pp. 3359-3364 (1991).
Buck, C.A., “Immunoglobulin superfamily: structure, function and relationship to other receptor molecules,”Seminars in Cell Biology, vol. 3, pp. 179-188 (1992).
Buelens, C. et al., “Interleukin 10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells,”Eur. J. Immunol., vol. 25, pp. 2668-2672 (1995).
Caruso, A. et al., “Expression of CD28 on CD8′ and CD44. Lymphocytes During HIV Infection,”Scand. J. Immunol., vol. 40, pp. 485-490 (1994).
Cerdan, C. et al., IL-1a is Produced by T Lymphocytes Activated Via the CD2 Plus CD28 Pathways,The Journal of Immunology, vol. 146, No. 2, pp. 560-564 (1991).
Chambers, C.A., et al., “Co-stimulation in T cell responses,”Current Opinion in Immunology, vol. 9, pp. 396-404 (1997).
Chen, L. et al., “Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4,”Cell, vol. 71, pp. 1093-1102 (1992).
Chen, L. et al., “Costimulation of T cells for tumor immunity,”Immunology Today, vol. 14, No. 10, pp. 483-486 (1993).
Chen, L. et al., “Induction of Cytotoxic T Lymphocytes Specific for a Syngeneic Tumor Expressing the E6 Oncoprotein of Human Papillomavirus Type 16,”The Journal of Immunology, vol. 148, No. 8, pp. 2617-2621 (1992).
Chesnut, R.W. et al., “Antigen Presentation by B Cells and its Significance in T-B Interactions,”Advances in Immunology, vol. 39, pp. 51-94 (1986).
Choi, I-S et al., “Mechanisms of Interaction between FIV infected and FIV effector T. Lymphocytes,”Dissertation, Texas A&M University, pp. 1-119 Dec. 1998.
Choi, I-S et al. “Sequence analyses of feline B7 costimulatory molecules”Veterinary Immunology and Immunopathology, vol. 73, No. 3-4 pp. 219-231, Mar. 15, 2000.
Clark, S.J. et al., “High Titers of Cytopathic Virus in Plasma of Patients With Symptomatic of Primary HIV-1 Infection,”The New England Journal of Medicine, vol. 324, No. 14, pp. 954-960 (1991).
Clayberger, C. et al., “Peptides Corresponding to the CD8 and CD4 Binding Domains of HLA Molecules Block T Lymphocyte Immune Responses In Vitro,”The Journal of Immunology, vol. 153, pp. 946-951 (1994).
Clevers, H. et al., “The T Cell Receptor/CD3 Complex: A Dynamic Protein Ensemble,”Annu. Re
Choi Insoo
Cochran Mark D.
Collisson Ellen W.
Winslow Barbara J.
Intervet Inc.
Loeb & Loeb LLP
Peng Bo
Texas A&M University System
LandOfFree
Feline CTLA-4 nucleic acid and polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Feline CTLA-4 nucleic acid and polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Feline CTLA-4 nucleic acid and polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205889